Study S003333

A Randomized, Open-label, Parallel, Treat to Target Study Comparing the Efficacy and Safety of HR17031 Injection With Insulin Glargine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin, Metformin in Combination With or Without One Other Oral Antidiabetic Drug (OAD)

ClinicalTrials.gov record

Registration

Registration: NCT06871761
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 393
Start: 2024-05-08
Primary completion: 2025-05-13
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Conditions: Adult Patients With Type 2 Diabetes
Interventions: DRUG:HR17031 injection; DRUG:insulin glargine
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Changes in HbA1c from baseline to week 26 [from baseline to week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.